Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

被引：89
|
作者：
Yee, Sook Wah [1 ,2 ]
Brackman, Deanna J. [1 ,2 ]
Ennis, Elizabeth A. [1 ,2 ]
Sugiyama, Yuichi [3 ]
Kamdem, Landry K. [4 ]
Blanchard, Rebecca [5 ]
Galetin, Aleksandra [6 ]
Zhang, Lei [7 ]
Giacomini, Kathleen M. [1 ,2 ,8 ]
机构：
[1] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[3] RIKEN, Res Cluster Innovat, RIKEN Innovat Ctr, Sugiyama Lab, Yokohama, Kanagawa, Japan
[4] Harding Univ, Coll Pharm, Dept Pharmaceut Sci, Searcy, AR USA
[5] CRISPR Therapeut, Cambridge, MA USA
[6] Univ Manchester, Sch Hlth Sci, Ctr Appl Pharmacokinet Res, Manchester, Lancs, England
[7] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[8] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 104卷 / 05期
关键词：
D O I：
10.1002/cpt.1098
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in genomic technologies have led to a wealth of information identifying genetic polymorphisms in membrane transporters, specifically how these polymorphisms affect drug disposition and response. This review describes the current perspective of the International Transporter Consortium(ITC) on clinically important polymorphisms in membrane transporters. ITC suggests that, in addition to previously recommended polymorphisms in ABCG2 (BCRP) and SLCO1B1 (OATP1B1), polymorphisms in the emerging transporter, SLC22A1 (OCT1), be considered during drug development. Collectively, polymorphisms in these transporters are important determinants of interindividual differences in the levels, toxicities, and response to many drugs.
引用
收藏
页码：803 / 817
页数：15
相关论文
共 50 条
  • [1] INFLUENCE OF TRANSPORTER POLYMORPHISMS ON DRUG DISPOSITION AND RESPONSE: A PERSPECTIVE FROM THE INTERNATIONAL TRANSPORTER CONSORTIUM
    Yee, Sook Wah
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S1 - S1
  • [2] Response from the International Transporter Consortium
    Caroline A. Lee
    Kathleen M. Hillgren
    Lei Zhang
    Joseph W. Polli
    Nature Reviews Drug Discovery, 2011, 10 : 75 - 75
  • [3] Response from the International Transporter Consortium
    Lee, Caroline A.
    Hillgren, Kathleen M.
    Zhang, Lei
    Polli, Joseph W.
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (01) : 75 - 75
  • [4] International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms
    Giacomini, K. M.
    Balimane, P. V.
    Cho, S. K.
    Eadon, M.
    Edeki, T.
    Hillgren, K. M.
    Huang, S-M
    Sugiyama, Y.
    Weitz, D.
    Wen, Y.
    Xia, C. Q.
    Yee, S. W.
    Zimdahl, H.
    Niemi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 23 - 26
  • [5] Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective
    Schlessinger, Avner
    Welch, Matthew A.
    van Vlijmen, Herman
    Korzekwa, Ken
    Swaan, Peter W.
    Matsson, Par
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 818 - 835
  • [6] Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms
    Pacanowski, Michael A.
    Hopley, Charles W.
    Aquilante, Christina L.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (05) : 529 - 544
  • [7] Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium
    Chu, Xiaoyan
    Liao, Mingxiang
    Shen, Hong
    Yoshida, Kenta
    Zur, Arik A.
    Arya, Vikram
    Galetin, Aleksandra
    Giacomini, Kathleen M.
    Hanna, Imad
    Kusuhara, Hiroyuki
    Lai, Yurong
    Rodrigues, David
    Sugiyama, Yuichi
    Zamek-Gliszczynski, Maciej J.
    Zhang, Lei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) : 836 - 864
  • [8] Transporter Studies in Drug Development: Experience to Date and Follow-Up on Decision Trees From the International Transporter Consortium
    Tweedie, D.
    Polli, J. W.
    Berglund, E. Gil
    Huang, S. M.
    Zhang, L.
    Poirier, A.
    Chu, X.
    Feng, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (01) : 113 - 125
  • [9] Highlights from the International Transporter Consortium Second Workshop
    Zamek-Gliszczynski, M. J.
    Hoffmaster, K. A.
    Tweedie, D. J.
    Giacomini, K. M.
    Hillgren, K. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) : 553 - 556
  • [10] Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans
    Kari T. Kivistö
    Mikko Niemi
    Pharmaceutical Research, 2007, 24 : 239 - 247
12345